Shinichi Kato

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 9

Top Venues

The Journal of pharmacology and experimental therapeutics

Clinical and experimental pharmacology & physiology

Drug development research

PloS one

Kyoto Pharmaceutical University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Kyoto Pharmaceutical University

Japan

Professor :: Division of Pathological Sciences, Department of Pharmacology and Experimental Therapeutics

Publications

Masumi Oka, Sohta Akaki, Osamu Ohno, Maho Terasaki, Yuho Hamaoka-Tamura, Michiko Saito, Shinichi Kato, Asuka Inoue, Junken Aoki, Kenji Matsuno, Kazuyuki Furuta, Satoshi Tanaka
Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate. The Journal of pharmacology and experimental therapeutics 389 (1) (2024)
Masumi Oka, Sohta Akaki, Osamu Ohno, Maho Terasaki, Yuho Hamaoka-Tamura, Michiko Saito, Shinichi Kato, Asuka Inoue, Junken Aoki, Kenji Matsuno, Kazuyuki Furuta, Satoshi Tanaka
Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate. The Journal of pharmacology and experimental therapeutics 389 (1) (2024)
Masumi Oka, Sohta Akaki, Osamu Ohno, Maho Terasaki, Yuho Hamaoka-Tamura, Michiko Saito, Shinichi Kato, Asuka Inoue, Junken Aoki, Kenji Matsuno, Kazuyuki Furuta, Satoshi Tanaka
Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate. The Journal of pharmacology and experimental therapeutics 389 (1) (2024)
Masumi Oka, Sohta Akaki, Osamu Ohno, Maho Terasaki, Yuho Hamaoka-Tamura, Michiko Saito, Shinichi Kato, Asuka Inoue, Junken Aoki, Kenji Matsuno, Kazuyuki Furuta, Satoshi Tanaka
Suppression of mast cell activation by GPR35: GPR35 is a primary target of disodium cromoglycate . The Journal of pharmacology and experimental therapeutics (2024)
Shinichi Kato, Suzuka Onishi, Misaki Sasai, Hiroyuki Yasuda, Kazuko Saeki, Kenjiro Matsumoto, Takehiko Yokomizo
Deficiency of leukotriene B4 receptor type 1 ameliorates ovalbumin-induced allergic enteritis in mice. Clinical and experimental pharmacology & physiology (2023)
Takehisa Noguchi, Kyosuke Hidaka, Satsuki Kobayashi, Kenjiro Matsumoto, Makoto Yoshioka, Xin Hu, David J Maloney, Shyh-Ming Yang, Shinichi Kato
A quinazoline-based bromodomain inhibitor, CN210, ameliorates indomethacin-induced ileitis in mice by inhibiting inflammatory cytokine expression. Drug development research 82 (8) (2021)
Shinichi Kato, Aoi Takahashi, Mai Shindo, Ayano Yoshida, Tomoe Kawamura, Kenjiro Matsumoto, Bunzo Matsuura
Characterization of the gastric motility response to human motilin and erythromycin in human motilin receptor-expressing transgenic mice. PloS one 14 (2) (2019)
Hiroyasu Sakai, Saori Yabe, Ken Sato, Yuki Kai, Fumiaki Sato, Tetsuro Yumoto, Yuka Inoue, Minoru Narita, Kenjiro Matsumoto, Shinichi Kato, Yoshihiko Chiba
ELR+ chemokine-mediated neutrophil recruitment is involved in 2,4,6-trinitrochlorobenzene-induced contact hypersensitivity. Clinical and experimental pharmacology & physiology 45 (1) (2017)
Shinichi Kato, Nahla Hamouda, Yoshitaro Kano, Yousuke Oikawa, Yoshiki Tanaka, Kenjiro Matsumoto, Kikuko Amagase, Masaki Shimakawa
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. Clinical and experimental pharmacology & physiology 44 (10) (2017)

Shinichi Kato.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shinichi Kato